Following up on its impressive Phase 1a trial data presented at last year's American Diabetes Association conference, Hua Medicine, an innovative, clinical-stage biotechnology company in Shanghai, announced positive results from its recently completed multicenter, multi-dose Phase 1b Trial in Diabetes.
Hua Medicine Ltd., an innovative, clinical-stage biotechnology company in Shanghai, announced the closing of a $25 million Series B financing.
Hua Medicine Ltd., a leading innovative drug development company in China, announced today the start of multicenter, multi-dose Phase 1b Trials for Diabetes.
Hua Medicine, the leading innovative drug development and commercialization company in China, and Roche announced today a licensing agreement for Roche's Glucokinase Activator (GKA) program.
Hua Medicine, the leading innovative drug development and commercialization company in China, announced today that it has secured $50 million in new financing commitments from a prestigious group of US and Chinese healthcare investors.
It is my great pleasure to announce that phase I clinical study of our novel Glucokinase activator HMS5552 started on September 2, 2013 at Shanghai Zhongshan Hospital Phase I clinical center in partner with TigerMed.
Copyright © 2019 Hua Medicine, All Rights Reserved沪ICP备14036654号